Effect of genetic polymorphism of glutahione S-transferases for the pharmacokinetics and adverse effects of oxaliplatin in patients with colorectal cancer

Effect of genetic polymorphism of glutahione S-transferases for the pharmacokinetics and adverse effects of oxaliplatin in patients with colorectal cancer - Effect of genetic polymorphism of glutahione S-transferases for the pharmacokinetics and adverse effects of oxaliplatin in patients with colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007460

Enrollment

Registered

2012-03-06

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Duration of study:2 years Dose of oxalipatin Times of blood sampling:11 times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patients with colorectal cancer who recieve mFOLFOX6+bevacizumab or mFOLFOX6 2.Performance Status:0~1

Exclusion criteria

Exclusion criteria: 1.patients with severe hepatotoxicity or nephrotoxicity 2.patients with neuropathy

Design outcomes

Primary

Measure	Time frame
genetic polymorphism of GST and PK parameter of L-OHP	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026